Prevention of Brain Metastasis by Inhibition of Angiogenesis? AyseguIlhan-Mutlu & Frank Winkler


Prevention of Brain Metastasis by Inhibition of Angiogenesis?

Department of Medicine I, Clinical Division of
Oncology, Medical University of Vienna,
Comprehensive Cancer Center, Vienna, Austria
Frank Winkler
Neurology Clinic & National Center for Tumor
Diseases, Ruprecht-Karls University , Clinical
Cooperation Unit Neurooncology, German Cancer
Research Center (DKFZ), Heidelberg, Germany
Corresponding author:
Prof. Dr. Frank Winkler,
Neurology Clinic and National Center for Tumor
Diseases, University Hospital Heidelberg &
German Cancer Research Center, Im Neuenheimer
Feld, D-69120 Heidelberg, Germany; phone:
00496221567107; fax: 00496221567554;

Brain metastasis (BM) is frequently observed in distinct tumor entities, including nonsquamous non-small-cell lung cancer (nsNSCLC, mainly lung adenocarcinoma) and triple negative and human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer (mBC)1. Lung cancer patients show by far the highest risk to develop BM during their disease: a current populationbased study demonstrated that 20%of all lung cancer patients will develop BM, compared with 6.5%of renal carcinoma, 6.9%of melanoma, and 5.1%of breast carcinoma
patients2. Given its high incidence, lung cancer is therefore responsible for about 60%of all BM2.

Leave a Reply

Your email address will not be published. Required fields are marked *